-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Is Now The Time To Put Prestige Consumer Healthcare (NYSE:PBH) On Your Watchlist?
Is Now The Time To Put Prestige Consumer Healthcare (NYSE:PBH) On Your Watchlist?
It's common for many investors, especially those who are inexperienced, to buy shares in companies with a good story even if these companies are loss-making. But the reality is that when a company loses money each year, for long enough, its investors will usually take their share of those losses. While a well funded company may sustain losses for years, it will need to generate a profit eventually, or else investors will move on and the company will wither away.
In contrast to all that, many investors prefer to focus on companies like Prestige Consumer Healthcare (NYSE:PBH), which has not only revenues, but also profits. Even if this company is fairly valued by the market, investors would agree that generating consistent profits will continue to provide Prestige Consumer Healthcare with the means to add long-term value to shareholders.
See our latest analysis for Prestige Consumer Healthcare
How Fast Is Prestige Consumer Healthcare Growing?
If you believe that markets are even vaguely efficient, then over the long term you'd expect a company's share price to follow its earnings per share (EPS) outcomes. That means EPS growth is considered a real positive by most successful long-term investors. To the delight of shareholders, Prestige Consumer Healthcare has achieved impressive annual EPS growth of 57%, compound, over the last three years. While that sort of growth rate isn't sustainable for long, it certainly catches the eye of prospective investors.
One way to double-check a company's growth is to look at how its revenue, and earnings before interest and tax (EBIT) margins are changing. EBIT margins for Prestige Consumer Healthcare remained fairly unchanged over the last year, however the company should be pleased to report its revenue growth for the period of 11% to US$1.1b. That's encouraging news for the company!
The chart below shows how the company's bottom and top lines have progressed over time. Click on the chart to see the exact numbers.
NYSE:PBH Earnings and Revenue History September 24th 2022You don't drive with your eyes on the rear-view mirror, so you might be more interested in this free report showing analyst forecasts for Prestige Consumer Healthcare's future profits.
Are Prestige Consumer Healthcare Insiders Aligned With All Shareholders?
It's a necessity that company leaders act in the best interest of shareholders and so insider investment always comes as a reassurance to the market. So it is good to see that Prestige Consumer Healthcare insiders have a significant amount of capital invested in the stock. Indeed, they hold US$23m worth of its stock. This considerable investment should help drive long-term value in the business. While their ownership only accounts for 0.9%, this is still a considerable amount at stake to encourage the business to maintain a strategy that will deliver value to shareholders.
It means a lot to see insiders invested in the business, but shareholders may be wondering if remuneration policies are in their best interest. Our quick analysis into CEO remuneration would seem to indicate they are. For companies with market capitalisations between US$2.0b and US$6.4b, like Prestige Consumer Healthcare, the median CEO pay is around US$6.9m.
Prestige Consumer Healthcare's CEO took home a total compensation package worth US$6.0m in the year leading up to March 2022. That comes in below the average for similar sized companies and seems pretty reasonable. While the level of CEO compensation shouldn't be the biggest factor in how the company is viewed, modest remuneration is a positive, because it suggests that the board keeps shareholder interests in mind. It can also be a sign of good governance, more generally.
Should You Add Prestige Consumer Healthcare To Your Watchlist?
Prestige Consumer Healthcare's earnings have taken off in quite an impressive fashion. The sweetener is that insiders have a mountain of stock, and the CEO remuneration is quite reasonable. The strong EPS improvement suggests the businesses is humming along. Big growth can make big winners, so the writing on the wall tells us that Prestige Consumer Healthcare is worth considering carefully. You still need to take note of risks, for example - Prestige Consumer Healthcare has 1 warning sign we think you should be aware of.
There's always the possibility of doing well buying stocks that are not growing earnings and do not have insiders buying shares. But for those who consider these important metrics, we encourage you to check out companies that do have those features. You can access a free list of them here.
Please note the insider transactions discussed in this article refer to reportable transactions in the relevant jurisdiction.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
對於許多投資者,尤其是那些缺乏經驗的投資者來説,購買有好故事的公司的股票是很常見的,即使這些公司在虧損。但現實是,當一家公司每年虧損時,在足夠長的時間內,投資者通常會承擔他們的損失份額。雖然一家資金雄厚的公司可能會虧損多年,但它最終需要創造利潤,否則投資者就會離開,公司就會枯萎。
與此形成鮮明對比的是,許多投資者更傾向於關注像威望消費者醫療保健(紐約證券交易所股票代碼:PBH),它不僅有收入,而且還有利潤。即使這家公司得到了市場的公平估值,投資者也會同意,產生持續的利潤將繼續為Prestige Consumer Healthcare提供為股東增加長期價值的手段。
查看我們對Prestige Consumer Healthcare的最新分析
Prestige Consumer Healthcare的增長速度有多快?
如果你相信市場是模糊有效的,那麼從長期來看,你會認為一家公司的股價會跟隨其每股收益(EPS)的結果。這意味着,大多數成功的長期投資者認為,每股收益的增長是一個真正的積極因素。令股東高興的是,Prestige Consumer Healthcare在過去三年中取得了令人印象深刻的57%的年每股收益複合增長率。儘管這種增長速度不會持續很長時間,但它肯定會吸引潛在投資者的目光。
要複核一家公司的增長,一種方法是觀察其收入和息税前利潤(EBIT)的變化情況。Prestige Consumer Healthcare的EBIT利潤率與去年持平,但該公司應高興地報告其收入增長11%至11億美元。這對公司來説是個鼓舞人心的消息!
下面的圖表顯示了該公司的利潤和收入是如何隨着時間的推移而變化的。點擊圖表查看確切的數字。
紐約證券交易所:PBH收益和收入歷史2022年9月24日你開車的時候眼睛不會盯着後視鏡,所以你可能會對這個更感興趣免費顯示分析師對Prestige Consumer Healthcare未來利潤。
Prestige Consumer Healthcare內部人員是否與所有股東一致?
公司領導人以股東的最佳利益行事是必要的,因此,內部投資總是對市場起到安撫作用。因此,很高興看到Prestige Consumer Healthcare內部人士將大量資本投資於該股。事實上,他們持有該公司價值2300萬美元的股票。這筆可觀的投資應該有助於推動業務的長期價值。雖然他們的持股只佔0.9%,但這仍然是一個相當大的風險,以鼓勵企業保持將為股東帶來價值的戰略。
看到內部人士投資於這項業務意義重大,但股東們可能會想,薪酬政策是否符合他們的最佳利益。我們對CEO薪酬的快速分析似乎表明,情況的確如此。對於市值在20億美元至64億美元之間的公司,如Prestige Consumer Healthcare,首席執行官的薪酬中值約為690萬美元。
在截至2022年3月的一年裏,威望消費者醫療保健公司的首席執行官獲得了總計600萬美元的薪酬方案。這低於類似規模公司的平均水平,似乎相當合理。雖然CEO的薪酬水平不應該是人們如何看待公司的最大因素,但適度的薪酬是一個積極的因素,因為它表明董事會考慮到了股東的利益。更廣泛地説,這也可能是良好治理的標誌。
您是否應該將Prestige Consumer Healthcare添加到您的觀察名單中?
威望消費者醫療保健公司的收益以令人印象深刻的方式增長。更令人欣慰的是,內部人士擁有堆積如山的股票,首席執行官的薪酬相當合理。每股收益的強勁改善表明,企業進展順利。大增長可以成為大贏家,所以不祥之兆告訴我們,Prestige Consumer Healthcare值得仔細考慮。您仍然需要注意風險,例如-Prestige Consumer Healthcare1個警告標誌我們認為你應該意識到。
總是有可能做得很好,購買股票不是不斷增長的收入和不要有內部人士購買股票。但對於那些考慮這些重要指標的人,我們建議您查看以下公司做擁有這些功能。你可以在這裏訪問它們的免費列表。
請注意,本文中討論的內幕交易指的是相關司法管轄區內的應報告交易。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧